The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
China Food and Drug Administration accept clinical trial application for JHL1101 in phase I and III trials in Non-Hodgkin Lymphoma
This month, on 4th April 2017, the China Food and Drug Administration (CFDA) accepted a Clinical Trial Application (CTA) by JHL Biotech for JH1101 in phase I and III clinical trials in NHL patients.1
JHL1101 is the first product in the company’s pipeline, and is a proposed biosimilar of rituximab.
JHL Biotech filed their application under the new guidelines for biosimilars issued in 2015 and data to support the CTA was produced at the company’s facility in Wuhan, China; the world's largest biopharmaceutical manufacturing facility based on single-use technologies.
In China, it is estimated that 80,000 cases of NHL are diagnosed each year.2
References